CJC-1295 + GHK-Cu Stack: When to Pick One, the Other, or Both

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

They are not two versions of the same thing

CJC-1295 is an investigational long-acting analogue of growth hormone-releasing hormone (GHRH) [1]. GHK-Cu is the copper(II) complex of a three-amino-acid peptide found in human plasma, saliva and urine, with levels reported to decline with age [9]. One is an unapproved injectable aimed at the pituitary; the other is mostly a skin-care ingredient with a few small human trials behind it.

CJC-1295 DAC has been studied for its effects on growth hormone and IGF-I in healthy volunteers [8]. The small human GHK-Cu trials tested topical products for skin or wound outcomes [3][4].

What CJC-1295 is, and how far its human data go

CJC-1295 comes in two described forms: a 29-amino-acid GHRH analogue, and CJC-1295 DAC, the same peptide with an extra maleimidopropionic acid-lysine unit that lets it bind blood albumin and last much longer [1][10]. In rats the long-acting form was still detectable in plasma beyond 72 hours [10]. In people, the estimated half-life after one subcutaneous injection was 5.8 to 8.1 days [8].

FDA's December 2024 review found no approved product containing any form of CJC-1295 in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain or the United Kingdom, and none authorized by the European Medicines Agency [1]. The agency identified only three published human studies, all of the DAC form and all in healthy volunteers [1].

Teichman 2006

Two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61. The first used single subcutaneous doses, the second two or three weekly or biweekly doses [8]. FDA counted 35 treated subjects and 7 on placebo in the first study [1]. After a single injection, mean plasma GH rose 2- to 10-fold for 6 days or more and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days; after multiple doses, IGF-I stayed above baseline for up to 28 days [8].

Ionescu and Frohman 2006

Healthy men aged 20 to 40 had one injection of 60 or 90 micrograms/kg. A week later, between-pulse (trough) GH was 7.5-fold higher (P<0.0001), mean GH was up 46% (P<0.01) and IGF-I up 45% (P<0.001), while the frequency and size of GH pulses were unchanged [11].

What the human record does not include: any study of a form of CJC-1295 in people with a disease, any study of the version sold as 'CJC-1295 without DAC', and any trial showing a health benefit [1].

What GHK-Cu is, and how far its human data go

The proposed actions of GHK-Cu come from laboratory and animal work summarised by the researchers who proposed them: stimulated collagen and proteoglycan production, modulation of metalloproteinases, attraction of immune and endothelial cells to injury, and faster wound healing in dogs, rats, mice and pigs [9]. Those are proposed mechanisms, not proven human effects.

No FDA-approved drug contains GHK-Cu [5]. Do not confuse it with copper histidinate (Zycubo), a different compound that FDA approved on January 12, 2026 for Menkes disease in children [12].

The 1992 venous ulcer trial

Eighty-six evaluable patients in a prospective randomized evaluator-blinded trial. A 0.4% tripeptide copper complex cream performed no differently from an inert vehicle placebo on ulcer size, while silver sulfadiazine 1% did reduce ulcer size [3].

The 2006 laser-resurfacing trial

Thirteen patients completed a randomized trial in which skin around the mouth was resurfaced with a CO2 laser and then treated with or without GHK-Cu. Computer analysis and blinded evaluators found no significant difference in resolution of redness, wrinkles or overall skin quality. A patient questionnaire did show a significant difference in overall skin quality favouring GHK-Cu (P=.04) [4].

The 2026 systematic review

The review kept 64 records published between 2005 and 2026 and concluded that, despite four decades of preclinical work, the human literature is thin and fragmented: most randomized trials are small, run on facial cosmetic creams, and microneedle delivery has not been tested in a single registered, adequately powered human randomized trial [13].

There is no FDA-approved GHK-Cu dose. Cosmetic strengths are set by manufacturers and are not reviewed by FDA; the only drug-style human trial found used a 0.4% cream [6][3].

Topical versus injectable: the difference that matters most

Whether a copper peptide product is a cosmetic or a drug depends on its intended use: claims to treat disease or to change the body's structure or function make it a drug, and cosmetics do not need FDA approval before sale [6]. Topical copper peptide creams and serums are therefore sold as cosmetics without FDA approval.

Injectable GHK-Cu is a different matter. It is not approved, and FDA's page on bulk substances that may raise significant safety risks lists it in the 'nominated but withdrawn' table with a stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [2]. Non-injectable GHK-Cu sits in FDA's category 1, the group under evaluation for the compounding bulks list, and FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027; no vote has happened yet [5][14].

CJC-1295 is in none of the three categories on FDA's list for state-licensed pharmacies and is not on the list for outsourcing facilities; it is not a component of an approved drug and has no USP monograph [5][15]. It was previously in category 2 (significant safety risks) and now sits in the 'nominated but withdrawn' table because the nominators withdrew; FDA's posted concerns remain, including possible immunogenicity, impurity and characterization problems, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited clinical data [2]. FDA's reviewers proposed in December 2024 that no form be added to the bulks list, and on December 4, 2024 the advisory committee voted 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms [16]. Neither peptide is among the six named in HHS's October 2026 draft enforcement-discretion policy [17]. Compounded drugs in general are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [18].

FDA also noted that CJC-1295 sold online is mostly labelled 'research use only', including blends with ipamorelin and GHRPs, and that such products are not approved drugs [1].

What to watch for

In the Teichman 2006 trials, injection-site reactions occurred in about 70% of treated subjects in study 1 and in all treated subjects in study 2; headache occurred in 63% versus 14% on placebo; flushing, warmth and transient low blood pressure affected about 30% of treated subjects in study 1; transient diarrhoea and, in two subjects, dizziness and low blood pressure were reported. Most events were more common at the higher doses of 125 or 250 micrograms/kg, and no serious adverse reactions were reported [1][8]. In the Ionescu and Frohman study, dose-dependent increases in heart rate and transient injection-site redness and tenderness were seen [1].

FDA's wider concern is that raising GH and IGF-I carries the risks listed on approved growth hormone labels, such as glucose intolerance and diabetes, fluid retention and tumour growth concerns, and that the human studies were short, small and mostly single-dose, so long-term safety is unknown [1]. ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. FDA cites anecdotal news reports that the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture; the data were never published, so a causal link is neither shown nor excluded [1].

For sport, WADA names CJC-1295 in section S2.2.4 and prohibits it at all times, in and out of competition [7][19]. GHK-Cu is not named on the 2026 or 2027 Prohibited List, but WADA's S0 class covers substances with no approval from any governmental health authority and the 2027 notes say peptides not specifically named may still be prohibited [7][20].

So when do you pick one, the other, or both?

If the interest is skin, the relevant product is a cosmetic cream sold without FDA review, and the human evidence is small and mixed: in the laser-resurfacing trial, objective measures showed no difference while patients reported better overall skin quality with GHK-Cu [4], and in the venous-ulcer trial the copper-peptide cream performed no better than placebo [3]; a 2026 review calls the clinical literature thin [13]. If the interest is raising growth hormone or IGF-I, no CJC-1295 product is approved anywhere FDA searched, the human data come from short healthy-volunteer studies of the DAC form at weight-based doses of about 30 to 250 micrograms/kg, and the peptide is prohibited by WADA [1][8][7].